The content on this site is intended for healthcare professionals only
Dr Abhishek Maiti speaks to ecancer in an online interview for the virtual ASH 2021 meeting about updated outcomes in genomic subgroups from a phase II trial of ten-day decitabine with venetoclax (DEC10-VEN) in acute myeloid leukaemia (AML).
He explains the background of this update, which found DEC10-VEN to offer better outcomes compared to intensive chemotherapy in older patients with newly diagnosed or relapsed/refractory AML.
Dr Maiti reports outcomes across various genomic subgroups, some of which were favourable while others were suboptimal.
TP53 mutations are linked to unfavourable prognosis in chronic lymphocytic leukaemia
Ponatinib is better than imatinib for frontline treatment of newly diagnosed Ph+ acute lymphoblastic leukaemia
Isatuximab in combination with pomalidomide and dexamethasone shows promising efficacy in 2nd line RRMM
ASCO 2024: Two studies report on isatuximab combos in transplant-ineligible patients with newly diagnosed multiple myeloma
Epitope editing enables targeted immunotherapy of acute myeloid leukaemia
Hodgkin’s and non-Hodgkin’s lymphomas (NHL)
Real-world use of brexu-cel shows benefit in R/R mantle cell lymphoma treatment
Triplets for newly diagnosed unfit AML patients could be feasible with substantial venetoclax reduction
Zanubrutinib demonstrates superior PFS compared with ibrutinib for treatment of R/R CLL and SLL
